Literature DB >> 2000961

N omega-nitro-L-arginine selectively inhibits vasodilator responses to acetylcholine and bradykinin in cats.

J A Bellan1, R K Minkes, D B McNamara, P J Kadowitz.   

Abstract

The effects of N omega-nitro-L-arginine (nitroarginine), an inhibitor of endothelium-dependent relaxing factor (EDRF) production, on vascular tone and responses to vasodilator and vasoconstrictor agents were investigated in the hindquarters vascular bed of the cat. Under constant flow conditions, infusion of nitroarginine into the hindquarters vascular bed caused a significant increase in systemic arterial and hindquarters perfusion pressures. During infusion of nitroarginine, hindquarters vasodilator responses to acetylcholine and bradykinin were reduced significantly whereas vasodilator responses to isoproterenol, PGE1, nitroprusside, and 8-bromoguanosine 3',5'-cyclic monophosphate were not altered. Infusion of nitroarginine significantly enhanced vasoconstrictor responses to the thromboxane receptor agonist U 46619 and to phenylephrine. The results of these studies are consistent with the hypotheses that EDRF production may involve the formation of nitric oxide or a nitroso compound from L-arginine, and that EDRF production may play a role in the regulation of vascular tone and in the mediation of responses to the endothelium-dependent vasodilators, acetylcholine and bradykinin, in resistance vessels in the hindquarters. These data support the concept that EDRF is very likely an endogenous nitrovasodilator derived from L-arginine in the hindquarters vascular bed of the cat.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2000961     DOI: 10.1152/ajpheart.1991.260.3.H1025

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  10 in total

Review 1.  Nitrates and nitrites in the treatment of ischemic cardiac disease.

Authors:  Vaughn E Nossaman; Bobby D Nossaman; Philip J Kadowitz
Journal:  Cardiol Rev       Date:  2010 Jul-Aug       Impact factor: 2.644

2.  Vasodilator responses to acetylcholine are not mediated by the activation of soluble guanylate cyclase or TRPV4 channels in the rat.

Authors:  Edward A Pankey; Modar Kassan; Soo-Kyoung Choi; Khalid Matrougui; Bobby D Nossaman; Albert L Hyman; Philip J Kadowitz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-03-21       Impact factor: 4.733

3.  Analysis of responses to human synthetic adrenomedullin and calcitonin gene-related peptides in the hindlimb vascular bed of the cat.

Authors:  H C Champion; D L Akers; J A Santiago; D G Lambert; D B McNamara; P J Kadowitz
Journal:  Mol Cell Biochem       Date:  1997-11       Impact factor: 3.396

4.  The Reemergence of Nitrite as a Beneficial Agent in the Treatment of Ischemic Cardiovascular Diseases.

Authors:  Bobby D Nossaman; Haseeb A Akuly; George F Lasker; Vaughn E Nossaman; Philip A Rothberg; Philip J Kadowitz
Journal:  Asian J Exp Biol Sci       Date:  2010-04

5.  Regulation of baseline vascular resistance in the canine diaphragm by nitric oxide.

Authors:  M E Ward; S N Hussain
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

6.  The effects of N omega-nitro-L-arginine methyl ester, sodium nitroprusside and noradrenaline on venous return in the anaesthetized cat.

Authors:  E A Bower; A C Law
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

7.  The action of Hoe 140 on the bradykinin-induced splenic pressor reflex of the anaesthetized cat.

Authors:  J B Louttit; R A Coleman
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

8.  Competitive inhibition of nitric oxide synthase prevents the cortical hyperemia associated with peripheral nerve stimulation.

Authors:  F J Northington; G P Matherne; R M Berne
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

9.  A comparison of the inhibitory effects of sodium nitroprusside, pinacidil and nifedipine on pressor response to NG-nitro-L-arginine.

Authors:  Y X Wang; T Zhou; C C Pang
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

10.  Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.

Authors:  Bobby Nossaman; Edward Pankey; Philip Kadowitz
Journal:  Crit Care Res Pract       Date:  2012-02-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.